KeyNeurotek Gets €8.2M for Overactive Bladder Program
BioWorld International Correspondent
KeyNeurotek Pharmaceuticals AG completed a second closing of an internal Series C round, raising the total value of the deal to €8.2 million (US$10.9 million).
Although no new investors bought into the company, all its "main existing investors" did participate, Magdeburg, Germany-based KeyNeurotek said.
Those include Munich-based Deutsche Venture Capital, IBG Beteiligungsgesellschaft, of Magdeburg, and Bonn-based KfW.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter